Alan Pollack1, Deukwoo Kwon2, Gail Walker2, Li Yan Khor3, Eric M Horwitz3, Mark K Buyyounouski4, Radka Stoyanova1. 1. Departments of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. 2. Biostatistics and Bioinformatics, University of Miami Miller School of Medicine, Miami, FL, USA. 3. Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 4. Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.
Abstract
Background: In prior retrospective studies, we assessed a number of prostate tumor tissue biomarkers that were associated independently with the clinical outcome of men treated with radiotherapy (RT) ±androgen deprivation therapy (ADT). In this report, the associations of selected biomarkers with biochemical or clinical disease failure (BCDF) were prospectively evaluated in men with T1-T3 prostate cancer on a randomized hypofractionation trial. Methods: Biomarkers were analyzed in 263 of 303 men randomly assigned tostandard vs moderate hypofractionation. Median follow-up was 65.9 months. Archival tissue was analyzed for Ki-67 (n = 231), MDM2 (n = 209), p16 (n = 195), Cox-2 (n = 126), p53 (n = 206), bcl2 (n = 223), bax (n = 210), and PKA (n = 160). The base model for multivariable Fine-Gray regression analysis included treatment assignment and risk groups. All statistical tests were two-sided. Results: Each biomarker was tested one at a time relative to the base model and selected for inclusion in multivariable analysis. Ki-67 (hazard ratio [HR] = 2.31, 95% confidence interval [CI] = 1.19 to 4.48, P = .01) and bcl2&bax (HR = 2.19, 95% CI = 1.08 to 4.46, P = .03) were statistically significantly related to higher BCDF and were independently statistically significant when considered jointly (Ki-67: HR = 2.26, 95% CI = 1.12 to 4.58, P = .02; bcl2&bax: HR = 2.14, 95% CI = 1.03 to 4.41, P = .04). At 2.5 years postradiotherapy, the C-index of Ki-67 was 73.2%, while for the base model was only 46.2%; Ki-67 was the most statistically significant when tested without bcl2&bax. Conclusions: In this prospective multiple biomarker analysis in men with prostate cancer treated with RT±ADT, both Ki-67 and bcl2&bax were independently related to early BCDF; however, Ki-67 alone is indicated to be the most clinically meaningful by C-index analysis and is universally available.
RCT Entities:
Background: In prior retrospective studies, we assessed a number of prostate tumor tissue biomarkers that were associated independently with the clinical outcome of men treated with radiotherapy (RT) ± androgen deprivation therapy (ADT). In this report, the associations of selected biomarkers with biochemical or clinical disease failure (BCDF) were prospectively evaluated in men with T1-T3 prostate cancer on a randomized hypofractionation trial. Methods: Biomarkers were analyzed in 263 of 303 men randomly assigned to standard vs moderate hypofractionation. Median follow-up was 65.9 months. Archival tissue was analyzed for Ki-67 (n = 231), MDM2 (n = 209), p16 (n = 195), Cox-2 (n = 126), p53 (n = 206), bcl2 (n = 223), bax (n = 210), and PKA (n = 160). The base model for multivariable Fine-Gray regression analysis included treatment assignment and risk groups. All statistical tests were two-sided. Results: Each biomarker was tested one at a time relative to the base model and selected for inclusion in multivariable analysis. Ki-67 (hazard ratio [HR] = 2.31, 95% confidence interval [CI] = 1.19 to 4.48, P = .01) and bcl2&bax (HR = 2.19, 95% CI = 1.08 to 4.46, P = .03) were statistically significantly related to higher BCDF and were independently statistically significant when considered jointly (Ki-67: HR = 2.26, 95% CI = 1.12 to 4.58, P = .02; bcl2&bax: HR = 2.14, 95% CI = 1.03 to 4.41, P = .04). At 2.5 years postradiotherapy, the C-index of Ki-67 was 73.2%, while for the base model was only 46.2%; Ki-67 was the most statistically significant when tested without bcl2&bax. Conclusions: In this prospective multiple biomarker analysis in men with prostate cancer treated with RT±ADT, both Ki-67 and bcl2&bax were independently related to early BCDF; however, Ki-67 alone is indicated to be the most clinically meaningful by C-index analysis and is universally available.
Authors: Mei-Yin C Polley; Boris Freidlin; Edward L Korn; Barbara A Conley; Jeffrey S Abrams; Lisa M McShane Journal: J Natl Cancer Inst Date: 2013-10-17 Impact factor: 13.506
Authors: Michael G Heckman; Alexander S Parker; Kevin J Wu; Tracy W Hilton; Stephen J Ko; Thomas M Pisansky; Steven E Schild; Li Yan Khor; Elizabeth H Hammond; Alan Pollack; Steven J Buskirk Journal: Prostate Date: 2012-04-18 Impact factor: 4.104
Authors: Radka Stoyanova; Niraj H Pahlajani; Brian L Egleston; Mark K Buyyounouski; David Y T Chen; Eric M Horwitz; Alan Pollack Journal: Cancer Date: 2012-10-23 Impact factor: 6.860
Authors: Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker Journal: Lancet Oncol Date: 2008-03-17 Impact factor: 41.316
Authors: Alan Pollack; Kyounghwa Bae; Li-Yan Khor; Tahseen Al-Saleem; M Elizabeth Hammond; Varagur Venkatesan; Roger W Byhardt; Sucha O Asbell; William U Shipley; Howard M Sandler Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Rile Li; Kateri Heydon; M Elizabeth Hammond; David J Grignon; Mack Roach; Harvey B Wolkov; Howard M Sandler; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Arnab Chakravarti; Michelle DeSilvio; Min Zhang; David Grignon; Seth Rosenthal; Sucha O Asbell; Gerald Hanks; Howard M Sandler; Li-Yan Khor; Alan Pollack; William Shipley Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Timothy N Clinton; Aditya Bagrodia; Yair Lotan; Vitaly Margulis; Ganesh V Raj; Solomon L Woldu Journal: Expert Rev Precis Med Drug Dev Date: 2017-09-05
Authors: Anna C Wilkins; Barry Gusterson; Zsolt Szijgyarto; Joanne Haviland; Clare Griffin; Christine Stuttle; Frances Daley; Catherine M Corbishley; David P Dearnaley; Emma Hall; Navita Somaiah Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-03 Impact factor: 7.038